|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
TuesdaySerono
linkSerono is the North American affiliate of Serono International SA. With nine recombinant molecules approved or under development, Serono International today ranks among the world’s leading biotechnology companies. Serono is the developer of Rebif (Interferon beta-1a)
Serono is committed to bringing hope to people suffering from multiple sclerosis. Rebif® is the leading treatment for Relapsing MS outside the US, and is the fastest growing MS treatment in the US. Several studies support the concept of maximal benefit with higher and more frequent doses of beta-interferon. With respect to interferon beta-1a administered subcutaneously, Rebif® 44 mcg, three times per week, has shown to achieve maximum treatment effect in terms of disease progression and reducing the frequency and severity of relapses |